FDG PET/CT显示使用GLP-1受体激动剂患者亚临床胰腺炎
一例83岁男性基底细胞癌患者行18F-FDG PET/CT分期,胰腺弥漫性放射性摄取增高而CT无异常,临床无症状但PET/CT后脂酶升高确诊胰腺炎。患者正在使用替尔泊肽(一种用于2型糖尿病和减重的GLP-1受体激动剂),未发现其他胰腺炎病因,故归因于该药物。
要点
- FDG PET/CT可显示胰腺弥漫性摄取增高而CT无异常,提示亚临床胰腺炎。
- 患者临床无症状,PET/CT后脂酶升高确诊胰腺炎。
- 未发现其他胰腺炎病因,病因归因于替尔泊肽。
核心结论
- 该患者胰腺弥漫性FDG摄取增高而CT无异常,临床无症状但脂酶升高,确诊亚临床胰腺炎。
- 未发现其他胰腺炎病因,病因归因于替尔泊肽。
研究设计与样本
- 病例报告:一例83岁男性基底细胞癌患者行18F-FDG PET/CT分期。
主要发现
- FDG PET/CT显示胰腺弥漫性放射性示踪剂摄取增高,CT无异常。
- 患者临床无症状,PET/CT后脂酶水平升高,确诊胰腺炎。
- 患者正在使用替尔泊肽(GLP-1受体激动剂),未发现其他胰腺炎病因,病因归因于该药物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An 83-year-old man with basal cell carcinoma was referred for an 18 F-FDG PET/CT scan for staging. The FDG PET/CT scan revealed diffuse increased radiotracer uptake within the pancreas without CT abnormality, which raised concern for pancreatitis. Although this man was clinically asymptomatic, a lipase level obtained after the PET/CT scan was elevated, confirming the diagnosis. This man was noted to be on tirzepatide, which is a GLP-1 receptor agonist medication used for type 2 diabetes and weight loss. No other causes of pancreatitis were identified in this man, and therefore, the cause was attributed to this medication.
引用
- Lenkov R, Berman T, Mehmi I, et al. FDG PET/CT Images Demonstrating Subclinical Pancreatitis in a Patient on a GLP-1 Receptor Agonist. Clin Nucl Med. 2025. PMID: 40103000. doi:10.1097/RLU.0000000000005856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。